J
138.76
-1.81 (-1.29%)
| 前收盘价格 | 140.57 |
| 收盘价格 | 138.99 |
| 成交量 | 3,630,832 |
| 平均成交量 (3个月) | 805,833 |
| 市值 | 8,427,241,472 |
| 市盈率 (P/E TTM) | 16.06 |
| 预期市盈率 (P/E Forward) | 4.79 |
| 价格/销量 (P/S) | 1.77 |
| 股市价格/股市净资产 (P/B) | 1.61 |
| 52周波幅 | |
| 利润日期 | 29 Apr 2025 - 5 May 2025 |
| 营业毛利率 | 13.77% |
| 营业利益率 (TTM) | 21.00% |
| 稀释每股收益 (EPS TTM) | 8.65 |
| 季度收入增长率 (YOY) | 7.50% |
| 季度盈利增长率 (YOY) | 103.00% |
| 总债务/股东权益 (D/E MRQ) | 150.64% |
| 流动比率 (MRQ) | 4.46 |
| 营业现金流 (OCF TTM) | 1.40 B |
| 杠杆自由现金流 (LFCF TTM) | 1.43 B |
| 资产报酬率 (ROA TTM) | 4.60% |
| 股东权益报酬率 (ROE TTM) | 14.31% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Jazz Pharmaceuticals plc | 看跌 | 看跌 |
AIStockmoo 评分
1.4
| 分析师共识 | 3.0 |
| 内部交易活动 | 2.5 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.40 |
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.09% |
| 机构持股比例 | 100.92% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 230.00 (Truist Securities, 65.75%) | 购买 |
| 中 | 179.00 (29.00%) | |
| 低 | 147.00 (Piper Sandler, 5.94%) | 购买 |
| 平均值 | 184.09 (32.67%) | |
| 总计 | 10 购买, 1 保留 | |
| 平均价格@调整类型 | 122.87 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Baird | 07 May 2025 | 155.00 (11.70%) | 购买 | 101.44 |
| Morgan Stanley | 07 May 2025 | 166.00 (19.63%) | 购买 | 101.44 |
| 07 Mar 2025 | 183.00 (31.88%) | 购买 | 138.81 | |
| Needham | 07 May 2025 | 200.00 (44.13%) | 购买 | 101.44 |
| 10 Apr 2025 | 210.00 (51.34%) | 购买 | 102.05 | |
| Piper Sandler | 07 May 2025 | 147.00 (5.94%) | 购买 | 101.44 |
| 26 Feb 2025 | 176.00 (26.84%) | 购买 | 144.17 | |
| RBC Capital | 07 May 2025 | 172.00 (23.96%) | 购买 | 101.44 |
| 26 Feb 2025 | 178.00 (28.28%) | 购买 | 144.17 | |
| HC Wainwright & Co. | 10 Mar 2025 | 217.00 (56.39%) | 购买 | 137.45 |
| UBS | 07 Mar 2025 | 179.00 (29.00%) | 购买 | 138.81 |
| Truist Securities | 06 Mar 2025 | 230.00 (65.75%) | 购买 | 136.45 |
| Barclays | 27 Feb 2025 | 200.00 (44.13%) | 购买 | 143.27 |
| Cantor Fitzgerald | 26 Feb 2025 | 150.00 (8.10%) | 保留 | 144.17 |
| JP Morgan | 26 Feb 2025 | 209.00 (50.62%) | 购买 | 144.17 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MULLIGAN SEAMUS | 103.58 | - | 1,621 | 167,903 |
| 累积净数量 | 1,621 | |||
| 累积净值 ($) | 167,903 | |||
| 累积平均购买 ($) | 103.58 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MULLIGAN SEAMUS | 董事 | 12 May 2025 | 买 (+) | 1,621 | 103.58 | 167,903 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合